Who Pays My Doctor?

Healthcare provider profile · identity verified

Leigh Ann Pansch, NP

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DAYTON, OH · NPI 1104138601

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Leigh Ann Pansch, NP received $193,126.46 in general payments during 2025 across 519 reported records.

Janssen Biotech, Inc. accounted for 23.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 34 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$193,126.46

519 reported records · 25 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $46,242.7223.9%652025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $29,119.8315.1%982025
UCB, Inc. Unresolved — no canonical attribution shown $27,678.5714.3%702025
Lilly USA, LLC Unresolved — no canonical attribution shown $15,269.007.9%352025
ABBVIE INC. Unresolved — no canonical attribution shown $12,301.626.4%542025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $11,444.795.9%162025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $9,165.984.8%272025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $8,482.184.4%212025
GENZYME CORPORATION Unresolved — no canonical attribution shown $7,876.314.1%172025
Eli Lilly and Company Unresolved — no canonical attribution shown $7,546.453.9%82025
Incyte Corporation Unresolved — no canonical attribution shown $6,607.103.4%202025
Amgen Inc. Unresolved — no canonical attribution shown $3,867.362.0%122025
LEO Pharma Inc. Unresolved — no canonical attribution shown $2,843.931.5%122025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $1,758.980.9%102025
LNHC, Inc Unresolved — no canonical attribution shown $1,680.580.9%22025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $341.180.2%142025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $276.520.1%142025
PFIZER INC. Unresolved — no canonical attribution shown $236.670.1%132025
Organon LLC Unresolved — no canonical attribution shown $131.960.1%22025
Mallinckrodt Hospital Products Inc. Unresolved — no canonical attribution shown $92.420.1%32025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $50.060.0%12025
Verrica Pharmaceuticals Inc. Unresolved — no canonical attribution shown $42.560.0%22025
Almirall LLC Unresolved — no canonical attribution shown $25.110.0%12025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $23.000.0%12025
Botanix SB Inc Unresolved — no canonical attribution shown $21.580.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$103,529.0068
Consulting Fee$48,746.0039
Travel and Lodging$28,988.99115
Food and Beverage$10,097.48292
Honoraria$1,600.001
Education$164.994

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc., Janssen Scientific Affairs, LLC $46,292.78 66 2025
Source payment records
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. $36,808.67 112 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $27,678.57 70 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Eli Lilly and Company, Lilly USA, LLC $19,595.44 37 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $11,725.72 35 2025
Source payment records
SPEVIGO
Normalized: spevigo		 Biological, Drug Boehringer Ingelheim Pharmaceuticals, Inc., LEO Pharma Inc. $11,464.01 17 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $7,645.83 23 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $6,521.90 15 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $3,989.29 17 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $3,867.36 12 2025
Source payment records
OLUMIANT
Normalized: olumiant		 Drug Eli Lilly and Company $1,875.00 2 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $1,742.79 9 2025
Source payment records
ZELSUVMI
Normalized: zelsuvmi		 Drug LNHC, Inc $1,680.58 2 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $1,165.65 4 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $931.56 5 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $292.09 11 2025
Source payment records
Zoryve
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc. $276.52 14 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $275.90 18 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $136.18 12 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $136.18 12 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $131.96 2 2025
Source payment records
ILUMYA
Normalized: ilumya		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $106.60 6 2025
Source payment records
ACTHAR
Normalized: acthar		 Biological Mallinckrodt Hospital Products Inc. $92.42 3 2025
Source payment records
HUMIRA
Normalized: humira		 Biological ABBVIE INC. $92.23 1 2025
Source payment records
YCANTH
Normalized: ycanth		 Drug Verrica Pharmaceuticals Inc. $42.56 2 2025
Source payment records
Winlevi
Normalized: winlevi		 Drug SUN PHARMACEUTICAL INDUSTRIES INC. $41.06 5 2025
Source payment records
Klisyri
Normalized: klisyri		 Drug Almirall LLC $25.11 1 2025
Source payment records
AYVAKIT
Normalized: ayvakit		 Biological GENZYME CORPORATION $23.05 1 2025
Source payment records
Cabtreo
Normalized: cabtreo		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $23.00 1 2025
Source payment records
  • 2025-10-14 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.00 · Open Payments source
Leqselvi
Normalized: leqselvi		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $21.75 1 2025
Source payment records
SOFDRA
Normalized: sofdra		 Drug Botanix SB Inc $21.58 1 2025
Source payment records
LIBTAYO
Normalized: libtayo		 Biological Regeneron Healthcare Solutions, Inc. $17.59 1 2025
Source payment records
AKLIEF
Normalized: aklief		 Drug Galderma Laboratories, L.P. $16.19 1 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $10.13 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Triamcinolone AcetonideTriamcinolone Acetonide14799
KetoconazoleKetoconazole9658
MetronidazoleMetronidazole8546
MupirocinMupirocin4532
Clobetasol PropionateClobetasol Propionate3626
CiclopiroxCiclopirox Olamine3316
HydrocortisoneHydrocortisone2919
FluorouracilFluorouracil2826
Mometasone FuroateMometasone Furoate16suppressed
Doxycycline HyclateDoxycycline Hyclate14suppressed
MinoxidilMinoxidil13suppressed
Dupixent PenDupilumab11suppressed
SpironolactoneSpironolactone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $193,126.46 · 519 records Janssen Biotech, Inc. ACTHAR, ADBRY, AKLIEF, ANZUPGO, AYVAKIT, Bimzelx, CIBINQO, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, HUMIRA, ILUMYA, Klisyri, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, OLUMIANT, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SKYRIZI, SOFDRA, SPEVIGO, Sotyktu, TALTZ, TREMFYA, VTAMA, Winlevi, YCANTH, ZELSUVMI, Zoryve — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error